Savara (SVRA) Competitors

$5.27 +0.02 (+0.38%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$5.28 +0.01 (+0.09%)

As of 06:30 AM Eastern

SVRA vs. NNNN, CRNX, TVTX, AMRX, and MANE

Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Anbio Biotechnology (NNNN), Crinetics Pharmaceuticals (CRNX), Travere Therapeutics (TVTX), Amneal Pharmaceuticals (AMRX), and MANE (MANE). These companies are all part of the "pharmaceutical products" industry.

How does Savara compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Savara (NASDAQ:SVRA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

: Savara has a consensus price target of $9.13, suggesting a potential upside of 73.15%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Anbio Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Savara
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
: Anbio Biotechnology's return on equity of 0.00% beat Savara's return on equity.
Company Net Margins Return on Equity Return on Assets
Anbio Biotechnology N/A N/A N/A
Savara N/A -84.01% -63.60%
: Anbio Biotechnology has higher revenue and earnings than Savara.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anbio Biotechnology $8.65M 442.48 $6.40M N/A N/A
Savara N/A N/A -$118.84M -$0.53 N/A
: In the previous week, Anbio Biotechnology had 1 more articles in the media than Savara. MarketBeat recorded 2 mentions for Anbio Biotechnology and 1 mentions for Savara. Anbio Biotechnology's average media sentiment score of 0.75 beat Savara's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anbio Biotechnology
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Anbio Biotechnology has a beta of 4.71, indicating that its stock price is 371% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
: 87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Savara	N/A	-84.01%	-63.60%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	442.48	$6.40M	N/A	N/A
Savara	N/A	N/A	-$118.84M	-$0.53	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anbio Biotechnology beats Savara on 7 of the 13 factors compared between the two stocks.

How does Savara compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

: Crinetics Pharmaceuticals currently has a consensus target price of $76.75, suggesting a potential upside of 84.01%. Savara has a consensus target price of $9.13, suggesting a potential upside of 73.15%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Savara.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.90
Savara
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
: Savara has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Crinetics Pharmaceuticals' return on equity of -41.46% beat Savara's return on equity.
Company Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals -6,046.22% -41.46% -37.43%
Savara N/A -84.01% -63.60%
: Savara has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Savara is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals $7.70M 571.16 -$465.32M -$4.94 N/A
Savara N/A N/A -$118.84M -$0.53 N/A
: In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Savara. MarketBeat recorded 4 mentions for Crinetics Pharmaceuticals and 1 mentions for Savara. Crinetics Pharmaceuticals' average media sentiment score of 0.36 beat Savara's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
: 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-6,046.22%	-41.46%	-37.43%
Savara	N/A	-84.01%	-63.60%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	571.16	-$465.32M	-$4.94	N/A
Savara	N/A	N/A	-$118.84M	-$0.53	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Crinetics Pharmaceuticals beats Savara on 10 of the 14 factors compared between the two stocks.

How does Savara compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

: In the previous week, Travere Therapeutics had 54 more articles in the media than Savara. MarketBeat recorded 55 mentions for Travere Therapeutics and 1 mentions for Savara. Travere Therapeutics' average media sentiment score of 0.29 beat Savara's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
24 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 87.9% of Savara shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Savara has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat Savara's return on equity.
Company Net Margins Return on Equity Return on Assets
Travere Therapeutics -4.00% -26.16% -3.71%
Savara N/A -84.01% -63.60%
: Travere Therapeutics currently has a consensus target price of $47.83, suggesting a potential upside of 7.02%. Savara has a consensus target price of $9.13, suggesting a potential upside of 73.15%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Travere Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
1 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
Savara
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
: Travere Therapeutics has higher revenue and earnings than Savara. Travere Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Travere Therapeutics $490.73M 8.47 -$25.55M -$0.23 N/A
Savara N/A N/A -$118.84M -$0.53 N/A
: Travere Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	24 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Savara	N/A	-84.01%	-63.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.47	-$25.55M	-$0.23	N/A
Savara	N/A	N/A	-$118.84M	-$0.53	N/A

Summary

Travere Therapeutics beats Savara on 9 of the 16 factors compared between the two stocks.

How does Savara compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

: In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Savara. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 1 mentions for Savara. Amneal Pharmaceuticals' average media sentiment score of 0.56 beat Savara's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amneal Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Amneal Pharmaceuticals has a net margin of 4.53% compared to Savara's net margin of 0.00%. Savara's return on equity of -84.01% beat Amneal Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Amneal Pharmaceuticals 4.53% -276.67% 7.60%
Savara N/A -84.01% -63.60%
: Amneal Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 10.13%. Savara has a consensus target price of $9.13, suggesting a potential upside of 73.15%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Amneal Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.75
Savara
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
: Amneal Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amneal Pharmaceuticals $3.02B 1.42 $72.06M $0.38 35.84
Savara N/A N/A -$118.84M -$0.53 N/A
: Amneal Pharmaceuticals has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.53%	-276.67%	7.60%
Savara	N/A	-84.01%	-63.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.42	$72.06M	$0.38	35.84
Savara	N/A	N/A	-$118.84M	-$0.53	N/A

Summary

Amneal Pharmaceuticals beats Savara on 10 of the 15 factors compared between the two stocks.

How does Savara compare to MANE?

Savara (NASDAQ:SVRA) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Savara N/A N/A -$118.84M -$0.53 N/A
MANE N/A N/A N/A N/A N/A
: MANE's return on equity of 0.00% beat Savara's return on equity.
Company Net Margins Return on Equity Return on Assets
Savara N/A -84.01% -63.60%
MANE N/A N/A N/A
: 87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Savara presently has a consensus target price of $9.13, suggesting a potential upside of 73.15%. MANE has a consensus target price of $83.33, suggesting a potential downside of 23.58%. Given Savara's higher possible upside, equities analysts clearly believe Savara is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Savara
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.78
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: In the previous week, MANE had 5 more articles in the media than Savara. MarketBeat recorded 6 mentions for MANE and 1 mentions for Savara. MANE's average media sentiment score of 0.68 beat Savara's score of 0.00 indicating that MANE is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MANE
4 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.53	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-84.01%	-63.60%
MANE	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MANE	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Savara and MANE tied by winning 5 of the 10 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.08B	$3.11B	$6.28B	$11.90B
Dividend Yield	N/A	1.89%	2.74%	5.26%
P/E Ratio	-9.94	18.52	29.17	27.35
Price / Sales	N/A	312.10	522.24	85.53
Price / Cash	N/A	56.01	43.42	54.56
Price / Book	5.27	4.36	9.82	6.79
Net Income	-$118.84M	$72.19M	$3.55B	$332.68M
7 Day Performance	0.57%	3.06%	2.33%	2.55%
1 Month Performance	-8.82%	7.96%	6.47%	9.36%
1 Year Performance	72.50%	51.72%	44.88%	45.22%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.7888 of 5 stars	$5.27 +0.4%	$9.13 +73.1%	+75.7%	$1.08B	N/A	N/A	20	Upcoming Earnings
NNNN Anbio Biotechnology	N/A	$29.98 +3.7%	N/A	N/A	$4.16B	$8.65M	N/A	27	News Coverage Gap Up
CRNX Crinetics Pharmaceuticals	2.8433 of 5 stars	$41.25 +5.7%	$76.75 +86.1%	+36.7%	$4.11B	$7.70M	N/A	210
TVTX Travere Therapeutics	1.6857 of 5 stars	$44.91 +1.8%	$43.50 -3.1%	+124.0%	$4.08B	$490.73M	N/A	460	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision Gap Down
AMRX Amneal Pharmaceuticals	2.9091 of 5 stars	$13.11 +2.2%	$15.00 +14.4%	+89.7%	$4.04B	$3.02B	34.50	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. NNNN, CRNX, TVTX, AMRX, and MANE

How does Savara compare to Anbio Biotechnology?

Summary

How does Savara compare to Crinetics Pharmaceuticals?

Summary

How does Savara compare to Travere Therapeutics?

Summary

How does Savara compare to Amneal Pharmaceuticals?

Summary

How does Savara compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. NNNN, CRNX, TVTX, AMRX, and MANE

How does Savara compare to Anbio Biotechnology?

Summary

How does Savara compare to Crinetics Pharmaceuticals?

Summary

How does Savara compare to Travere Therapeutics?

Summary

How does Savara compare to Amneal Pharmaceuticals?

Summary

How does Savara compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools